These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 24477907)

  • 1. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge.
    Bouwer AL; Saunderson SC; Caldwell FJ; Damani TT; Pelham SJ; Dunn AC; Jack RW; Stoitzner P; McLellan AD
    J Immunol; 2014 Mar; 192(5):2514-21. PubMed ID: 24477907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
    Wargo JA; Schumacher LY; Comin-Anduix B; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS; Ribas A
    Cancer Gene Ther; 2005 Jun; 12(6):516-27. PubMed ID: 15775996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
    Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
    Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
    Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
    Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
    Homma S; Komita H; Sagawa Y; Ohno T; Toda G
    Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DC therapy induces long-term NK reactivity to tumors via host DC.
    Shimizu K; Fujii S
    Eur J Immunol; 2009 Feb; 39(2):457-68. PubMed ID: 19180466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza A infection by IFN-γ and perforin-dependent mechanisms.
    Ge MQ; Ho AW; Tang Y; Wong KH; Chua BY; Gasser S; Kemeny DM
    J Immunol; 2012 Sep; 189(5):2099-109. PubMed ID: 22869906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway.
    Nagasaki E; Takahara A; Koido S; Sagawa Y; Aiba K; Tajiri H; Yagita H; Homma S
    J Immunother; 2010 Jun; 33(5):467-74. PubMed ID: 20463601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
    Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
    Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.